FDA Advisory Committee recommends raxibacumab (HGS), for Anthrax
The FDA Anti-Infective Drugs Advisory Committee (AIDAC) voted 16-1, with one abstention, that animal studies conducted by Human Genome Sciences of raxibacumab, an injectable recombinant fully human monoclonal antibody that targets the protective antigen component of the lethal toxin of Bacillus anthracis, provided substantial evidence the drug, with or without antimicrobials, was reasonably likely to produce clinical benefit as a treatment for inhalational anthrax in humans.
The FDA is expected to make a decision by 15 December.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins